Study to Determine the Impact of BreatheSmart on Asthma Control in Adult Asthmatics

Inclusion Criteria: Male and/or female adults (aged ≥ 18 years) Ability to provide written informed consent Owns a compatible smartphone (iOS 8.0 or higher, or Android 4.3 or higher) and is familiar with the download and management of software applications Diagnosis of persistent asthma for at least 6 months duration with evidence of poorly controlled disease defined as having at least one of the following within 12 months prior to consent: exacerbation of asthma symptoms requiring pulse of corticosteroids acute asthma event that resulted in an emergency department or urgent care visit hospitalization for asthma related care Managed on inhaled corticosteroid (ICS) medication for at least 3 months prior to enrollment. Stable dose of oral corticosteroids and/or biologic therapy is also permissable Use of a pressurized metered dose inhaler (pMDI) compatible with the HeroTracker Non-smoker, or ≤ 10 pack/year history of tobacco use and abstinence for at least 1 year Exclusion Criteria: Presence of other significant chronic lung disease or condition such as chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, chronic lung disease of prematurity, recurrent aspiration, primary pulmonary hypertension, or presence of tracheostomy Presence of other chronic medical conditions such as congenital heart disease or immunodeficiency, Presence of other comorbidities that, in the opinion of the investigator, will interfere with the collection of study procedures, or limit life expectancy to < 1 year Currently pregnant/breast feeding or planning to become pregnant during the study period Primary language other than English or Spanish